LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 408

Suchoptionen

  1. Artikel ; Online: Is Immunotherapy With Concomitant Proton Pump Inhibitor Use a Viable Combination?

    Stefani, Alessio / Bria, Emilio

    JAMA network open

    2023  Band 6, Heft 7, Seite(n) e2322922

    Mesh-Begriff(e) Humans ; Proton Pump Inhibitors/therapeutic use ; Immunotherapy
    Chemische Substanzen Proton Pump Inhibitors
    Sprache Englisch
    Erscheinungsdatum 2023-07-03
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Comment
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2023.22922
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Extension of the SPIRIT 2013 Statement for Factorial Randomized Trials-A Step Toward Transparency and the Curse of Interaction.

    Mastrantoni, Luca / Daniele, Gennaro / Bria, Emilio

    JAMA network open

    2023  Band 6, Heft 12, Seite(n) e2346124

    Mesh-Begriff(e) Humans ; Randomized Controlled Trials as Topic ; Research Design ; Checklist
    Sprache Englisch
    Erscheinungsdatum 2023-12-01
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2023.46124
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Seize the Opportunity With Small Tissue Samples: The Tailor Teaches!

    Trisolini, Rocco / Bria, Emilio / Cetoretta, Valeria / Viscuso, Marta / Malapelle, Umberto

    JTO clinical and research reports

    2023  Band 4, Heft 4, Seite(n) 100507

    Sprache Englisch
    Erscheinungsdatum 2023-03-24
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2666-3643
    ISSN (online) 2666-3643
    DOI 10.1016/j.jtocrr.2023.100507
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel: Looking for a better measure of the benefit in clinical trials: a never-ending journey.

    Daniele, Gennaro / Giannarelli, Diana / Bria, Emilio

    Annals of translational medicine

    2020  Band 8, Heft 14, Seite(n) 893

    Sprache Englisch
    Erscheinungsdatum 2020-07-22
    Erscheinungsland China
    Dokumenttyp Editorial ; Comment
    ZDB-ID 2893931-1
    ISSN 2305-5847 ; 2305-5839
    ISSN (online) 2305-5847
    ISSN 2305-5839
    DOI 10.21037/atm.2020.03.118
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: Biosimilars as a strategy to improve sustainability.

    Bria, Emilio / Conte, Pierfranco

    ESMO open

    2017  Band 2, Heft 2, Seite(n) e000192

    Sprache Englisch
    Erscheinungsdatum 2017-05-29
    Erscheinungsland England
    Dokumenttyp Editorial ; Comment
    ISSN 2059-7029
    ISSN 2059-7029
    DOI 10.1136/esmoopen-2017-000192
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel: Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing?

    Malapelle, Umberto / Rossi, Antonio / Bria, Emilio

    Journal of thoracic disease

    2019  Band 11, Heft Suppl 15, Seite(n) S1837–S1840

    Sprache Englisch
    Erscheinungsdatum 2019-09-30
    Erscheinungsland China
    Dokumenttyp Editorial ; Comment
    ZDB-ID 2573571-8
    ISSN 2077-6624 ; 2072-1439
    ISSN (online) 2077-6624
    ISSN 2072-1439
    DOI 10.21037/jtd.2019.08.99
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Response to first-line pembrolizumab in metastatic

    Rossi, Sabrina / Pagliaro, Arianna / Finocchiaro, Giovanna / Marinello, Arianna / Giordano, Laura / Bria, Emilio / Stefani, Alessio / Vitale, Antonio / Toschi, Luca / D'Argento, Ettore / Santoro, Armando

    Future oncology (London, England)

    2024  Band 20, Heft 7, Seite(n) 373–380

    Abstract: Aims: ...

    Abstract Aims:
    Mesh-Begriff(e) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Proto-Oncogene Proteins p21(ras)/genetics ; Retrospective Studies ; Antibodies, Monoclonal, Humanized
    Chemische Substanzen pembrolizumab (DPT0O3T46P) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2) ; KRAS protein, human ; Antibodies, Monoclonal, Humanized
    Sprache Englisch
    Erscheinungsdatum 2024-03-06
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2274956-1
    ISSN 1744-8301 ; 1479-6694
    ISSN (online) 1744-8301
    ISSN 1479-6694
    DOI 10.2217/fon-2023-0952
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches.

    Cencioni, Chiara / Trestini, Ilaria / Piro, Geny / Bria, Emilio / Tortora, Giampaolo / Carbone, Carmine / Spallotta, Francesco

    Nutrients

    2022  Band 14, Heft 8

    Abstract: Nutritional habits impinge on the health of the gastrointestinal (GI) tract, contributing to GI disorder progression. GI cancer is a widespread and aggressive tumor sensitive to nutritional changes. Indeed, specific nutritional expedients can be adopted ... ...

    Abstract Nutritional habits impinge on the health of the gastrointestinal (GI) tract, contributing to GI disorder progression. GI cancer is a widespread and aggressive tumor sensitive to nutritional changes. Indeed, specific nutritional expedients can be adopted to prevent GI cancer onset and to slow down disease activity. Moreover, the patient's nutritional status impacts prognosis, quality of life, and chemotherapy tolerance. These patients encounter the highest frequency of malnourishment risk, a condition that can progressively evolve into cachexia. Clinical studies dealing with this topic stressed the importance of nutritional counseling and put under the spotlight nutrient delivery, the type of nutrient supplementation, and timing for the start of nutritional management. A medical practitioner well-prepared on the topic of nutrition and cancer should operate in the clinical team dedicated to these oncological patients. This specific expertise needs to be implemented as soon as possible to adopt nutritional interventions and establish a proper patient-tailored dietary regimen. The nutritional gap closure should be prompt during anticancer treatment to stabilize weight loss, improve treatment tolerability, and ameliorate survival rate. Recently, novel nutritional approaches were investigated to target the bidirectional link between epigenetics and metabolism, whose alteration supports the onset, progression, and therapeutic response of GI cancer patients.
    Mesh-Begriff(e) Cachexia/therapy ; Epigenesis, Genetic ; Gastrointestinal Neoplasms/genetics ; Humans ; Neoplasms/metabolism ; Nutritional Status ; Quality of Life
    Sprache Englisch
    Erscheinungsdatum 2022-04-08
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2518386-2
    ISSN 2072-6643 ; 2072-6643
    ISSN (online) 2072-6643
    ISSN 2072-6643
    DOI 10.3390/nu14081542
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.

    Mastrantoni, Luca / Orlandi, Armando / Palazzo, Antonella / Garufi, Giovanna / Fabi, Alessandra / Daniele, Gennaro / Giannarelli, Diana / Tortora, Giampaolo / Bria, Emilio

    EClinicalMedicine

    2023  Band 56, Seite(n) 101824

    Abstract: Background: In hormone-receptor positive/HER2-negative metastatic breast cancer (mBC) no randomized comparisons are available between CDK4/6 inhibitors. We undertook this systematic review and meta-analysis to assess the reliability of the likelihood of ...

    Abstract Background: In hormone-receptor positive/HER2-negative metastatic breast cancer (mBC) no randomized comparisons are available between CDK4/6 inhibitors. We undertook this systematic review and meta-analysis to assess the reliability of the likelihood of being helped or harmed (LHH).
    Methods: PubMed, CENTRAL, Embase and oncological meetings websites were searched to September 13th, 2022. We included phase III randomized controlled trials (RCTs) investigating palbociclib, ribociclib and abemaciclib in addition to endocrine therapy (ET) compared to placebo in hormone-receptor positive/HER2-negative advanced or mBC. Outcomes were progression-free survival (PFS), overall survival (OS), adverse events (AEs), dose reductions and discontinuations. Hazard ratios (HRs) and risk differences were computed with a random effect model to estimate the number needed to treat/harm (NNT/NNH). LHH was computed as (1/NNT)/(1/NNH). PROSPERO registration number: CRD42022362417.
    Findings: 2204 records were screened and seven RCTs (4415 patients) were included. A significant PFS benefit was observed in patients treated with a CDK4/6 inhibitor compared to placebo (HR 0.549; 0.508-0.594,
    Interpretation: Palbociclib and ribociclib showed lower LHHs for haematological toxicities and abemaciclib for diarrhea. Palbociclib confirmed to be a manageable drug. The LHH appears to be a reliable synthesis tool for balancing risks and benefits of experimental drugs when head-to-head comparisons are missing.
    Funding: None.
    Sprache Englisch
    Erscheinungsdatum 2023-01-20
    Erscheinungsland England
    Dokumenttyp Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2023.101824
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel: Bronchoscopically-visible massive central airway cancer cavitation is associated with metastatic disease, lack of actionable mutations and poor prognosis: a case series.

    Magnini, Daniele / Bria, Emilio / Cancellieri, Alessandra / Livi, Vanina / Leoncini, Fausto / Ferrari, Marco / Bruni, Teresa / Paioli, Daniela / Trisolini, Rocco

    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace

    2023  

    Abstract: Cavitating lung tumors occur in approximately 10-15% of the patients, are more commonly associated with squamous histology, and are typically located in the lung parenchyma. Herein we describe an exceedingly rare series of 5 patients, 4 of whom treatment- ...

    Abstract Cavitating lung tumors occur in approximately 10-15% of the patients, are more commonly associated with squamous histology, and are typically located in the lung parenchyma. Herein we describe an exceedingly rare series of 5 patients, 4 of whom treatment-naïve, whose tumor caused the disruption of the normal airway anatomy at the level of lobar or segmental bronchi, leading to the formation of an endoscopically-visible cavity which ended up in the lung parenchyma or even into the pleural space. Sex (3 males, 2 females), smoking habit (2 never smokers, 2 former smokers, 1 current smoker), and histology (3 adenocarcinoma, 2 squamous cell carcinoma) were heterogeneous, but the 4 patients treatment-naïve presented with metastatic disease, poor ECOG performance status, similar clinical complaints of long duration, and lack of actionable mutations. The only patient who exhibited a meaningful response to treatment had the lowest symptoms' duration, the smallest size of the cavitated mass, and the best performance status at the time of diagnosis. This series provides the first comprehensive description of a rare presentation of lung cancer characterized by similar clinical complaints, delayed diagnosis and poor prognosis.
    Sprache Englisch
    Erscheinungsdatum 2023-10-03
    Erscheinungsland Italy
    Dokumenttyp Journal Article
    ZDB-ID 1160940-0
    ISSN 1122-0643 ; 1120-0391
    ISSN 1122-0643 ; 1120-0391
    DOI 10.4081/monaldi.2023.2670
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang